Brentuximab Vedotin (SGN-35), an antibodydrug conjugate for the treatment of CD30-positive malignancies

Expert Opinion on Investigational Drugs

Volumn 21, Issue 2, 2012, Pages 205-216

  Gualberto, Antonio ^a,b  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Anaplastic large cell lymphoma; Antibodydrug conjugate; Brentuximab vedotin; CAC10; CD30; Hodgkin lymphoma; Monomethyl auristatin E; SGN 35; TNFSFR8

Indexed keywords

BLEOMYCIN; BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; VINBLASTINE; VINCRISTINE;

ACUTE KIDNEY FAILURE; ALLOGENEIC STEM CELL TRANSPLANTATION; ANAPHYLAXIS; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SIZE; CANCER SURVIVAL; CHILL; COUGHING; DEMYELINATING NEUROPATHY; DEMYELINATING POLYNEUROPATHY; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EXCRETION; DRUG FEVER; DRUG SAFETY; DRUG STRUCTURE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; INFECTION; LARGE CELL LYMPHOMA; LYMPHOMATOID PAPULOSIS; LYMPHOPROLIFERATIVE DISEASE; MOTOR NEUROPATHY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MYALGIA; MYCOSIS FUNGOIDES; NAUSEA; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROGRESSION FREE SURVIVAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROSTATITIS; PRURITUS; REVIEW; SENSORY NEUROPATHY; SEPTIC SHOCK; SEZARY SYNDROME; SIDE EFFECT; STEVENS JOHNSON SYNDROME; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ANTIGENS, CD30; ANTINEOPLASTIC AGENTS; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; LYMPHOMA, LARGE-CELL, ANAPLASTIC;

EID: 84855789037     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2011.641532     Document Type: Review

References (67)

1. Connors JM. State-of-the-art therapeutics: hodgkin's lymphoma. J Clin Oncol 2005;23:6400-8 (Pubitemid 46222240)
2. Carde P, Johnson P. Principles of chemotherapy in Hodgkin lymphoma. In: Engert A, Horning SJ, editors. Hodgkin lymphoma: a comprehensive update on diagnostics and clinics. Springer-Verlag; Berlin Heidelberg: 2010. p. 141-61
3. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-84
4. Kuppers R, Yahalom J, Josting A. Advances in biology, diagnostics, and treatment of Hodgkin's disease. Biol Blood Marrow Transplant 2006;12:66-76 (Pubitemid 43034123)
5. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:4634-42 (Pubitemid 46237440)
6. Horning SJ, Chao NJ, Negrin RS, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997;89:801-13 (Pubitemid 27121273)
7. Kleiner S, Kirsch A, Schwaner I, et al. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study. Bone Marrow Transplant 1997;20:953-9 (Pubitemid 27510958)
8. Baker KS, Gordon BG, Gross TG, et al. Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents. J Clin Oncol 1999;17:825-31 (Pubitemid 29109312)
9. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506-14
10. Horning S, Fanale M, de Vos S, et al. Defining a population of Hodgkin lymphoma patients for novel therapeutics: an international effort [abstract]. Ann Oncol 2008;19:iv120-1
11. Martinez C, Canals C, Alessandrino E, et al. Relapse of Hodgkin's lymphoma (HL) after autologous stem cell transplantation (ASCT): Prognostic factors in 462 patients registered in the database of the EBMT [abstract]. J Clin Oncol 2010;28:588s
12. Sureda A, Constans M, Iriondo A, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005;16:625-33 (Pubitemid 40613330)
13. Moskowitz CH, Kewalramani T, Nimer SD, et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004;124:645-52 (Pubitemid 38297098)
14. Jacobsen E. Anaplastic large-cell lymphoma, T-/null-cell type. Oncologist 2006;11:831-40 (Pubitemid 44157571)
15. Tilly H, Gaulard P, Lepage E, et al. Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome. Blood 1997;90:3727-34 (Pubitemid 27473445)
16. Filippa DA, Ladanyi M, Wollner N, et al. CD30 (Ki-1)-positive malignant lymphomas: clinical, immunophenotypic, histologic, and genetic characteristics and differences with Hodgkin's disease. Blood 1996;87:2905-17
17. Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000;96:3681-95
18. Weisenburger DD, Anderson JR, Diebold J, et al. Systemic anaplastic large-cell lymphoma: results from the non-Hodgkin's lymphoma classification project. Am J Hematol 2001;67:172-8 (Pubitemid 32538615)
19. Delsol G, Falini B, Muller-Hermelink HK, et al. Anaplastic large-cell lymphoma, ALK-positive. In: Swerdlow SH, Campo E, Harris NL, et al. editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. International Agency for Research on Cancer; Lyon, France: 2008. p. 312-16
20. Savage KJ, Harris NL, Vose JM, et al. ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111:5496-504
21. Savage KJ. Aggressive peripheral T-cell lymphomas (specified and unspecified types). Hematology Am Soc Hematol Educ Program 2005;267-77
22. Savage KJ. Prognosis and primary therapy in peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program 2008;280-8
23. Stain H, Delsol G, Pileri SA, et al. Classical Hodgkin Lymphoma, Introduction. In: Swerdlow SH, Campo E, Harris NL, et al. editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. International Agency for Research on Cancer; Lyon, France: 2008. p. 326-9
24. Mason DY, Harris NL, Delsol G, et al. Anaplastic large-cell lymphoma, ALK-negative. In: Swerdlow SH, Campo E, Harris NL, et al. editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th Edition. International Agency for Research on Cancer; Lyon, France: 2008. p. 317-19
25. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985;66:848-58 (Pubitemid 15242469)
26. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. International Agency for Research on Cancer; Lyon, France: 2008
27. Falini B, Pileri S, Pizzolo G, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995;85(1):14
28. Oflazoglu E, Grewal IS, Gerber H. Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. Adv Exp Med Biol 2009;647:174-85
29. Al-Shamkhani A. The role of CD30 in the pathogenesis of haematopoietic malignancies. Curr Opin Pharmacol 2004;4:355-9 (Pubitemid 38987061)
30. Gerber HP. Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma. Biochem Pharmacol 2010;79:1544-52
31. Guo F, Sun A, Wang W, et al. TRAF1 is involved in the classical NF-kappaB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells. Mol Immunol 2009;46:2441-8
32. Hirsch B, Hummel M, Bentink S, et al. CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells. Am J Pathol 2008;172:510-20 (Pubitemid 351282036)
33. Horie R, Higashihara M, Watanabe T. Hodgkin's lymphoma and CD30 signal transduction. Int J Hematol 2003;77:37-47 (Pubitemid 37127584)
34. Wright CW, Rumble JM, Duckett CS. CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells. J Biol Chem 2007;282:10252-62 (Pubitemid 47093448)
35. Amakawa R, Hakem A, Kundig TM, et al. Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. Cell 1996;84:551-62
36. Chiarle R, Podda A, Prolla G, et al. CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway. J Immunol 1999;163:194-205 (Pubitemid 29295841)
37. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003;102:1458-65 (Pubitemid 36988057)
38. Okeley NM, Miyamoto JB, Zhang X, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 2010;16:888-97
39. Senter PD. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 2009;13:235-44
40. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-21
41. Seattle Genetics, Inc. ADCETRIS (brentuximab vedotin) for Injection. Full Prescribing Information 2011. Available from: www.adcetris.com/-pdf/ADCETRIS- PromoPI-20110825.pdf
42. Bartlett N, Grove LE, Kennedy DA, et al. Objective responses with brentuximab vedotin (SGN-35) retreatment in CD30-positive hematologic malignancies: a case series [abstract]. J Clin Oncol 2010;28:8062
43. Fanale M, Bartlett NL, Forero-Torres A, et al. The antibody-drug conjugate brentuximab vedotin (SGN-35) induced multiple objective responses in patients with relapsed or refractory CD30-positive lymphomas in a phase 1 weekly dosing study [abstract]. Blood 2009;114:1068-9
44. Chen RW, Gopal AK, Smith SE, et al. Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL) [abstract]. J Clin Oncol 2011;29:8031
45. Younes A, Gopal AK, Smith SE, et al. Durable complete remissions in a pivotal phase 2 study of SGN-35 (brentuximab vedotin) in patients with relapsed or refractory Hodgkin lymphoma (HL) [abstract]. Ann Oncol 2011;22:iv138
46. Pro B, Advani R, Brice P, et al. Durable remissions with brentuximab vedotin (SGN-35): updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL) [abstract]. J Clin Oncol 2011;29:8032
47. Shustov AR, Advani R, Brice P, et al. Durable remissions with SGN-35 (brentuximab vedotin): updated results of a phase 2 study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL) [abstract]. Ann Oncol 2011;22:iv125
48. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86 (Pubitemid 350002966)
49. Chen R, Gopal AK, Smith SE, et al. Results of a pivotal phase 2 study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma [abstract]. Blood 2010;116:128-9
50. Shustov AR, Advani R, Brice P, et al. Complete remissions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma [abstract]. Blood 2010;116:423-4
51. Advani R, Fanale M, Brice P, et al. Resolution of malignant cutaneous lesions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma [abstract]. Haematologica 2011;96:154
52. Gopal AK, Ramchandren R, Berryman RB, et al. Brentuximab vedotin (SGN-35) treatment in relapsed CD30-positive Hodgkin's lymphoma patients following allogeneic stem cell transplant: a multi-center case series [abstract]. Bone Marrow Transplant 2011;46:S1-S89
53. Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008;26:455-62 (Pubitemid 351171699)
54. Carlson K, Ocean AJ. Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach. Clin Breast Cancer 2011;11:73-81
55. Swain SM, Arezzo JC. Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol 2008;6:455-67
56. Seattle Genetics, Inc. Brentuximab vedotin (SGN-35). FDA Oncologic Drugs Advisory Committee (ODAC) briefing document (BLA 125399) 2011. Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ OncologicDrugsAdvisoryCommittee/UCM262598.pdf
57. Kesselheim AS, Myers JA, Avorn J. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA 2011;305:2320-6
58. Josting A, Schmitz N. Insights into 25 years of clinical trials of the GHSG: relapsed and refractory Hodgkin's disease. In: Diehl V, Josting A, editors. 25 years German Hodgkin Study Group. Urban & Voegel; Munich: 2004. p. 89-99
59. Lee L, Wang L, Crump M. Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points. Ann Oncol 2011;22:1392-403
60. Advani R, Forero-Torres A, Fanale M, et al. Objective responses with brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL) who refused or were ineligible for autologous stem cell transplantation (ASCT) [abstract]. Haematologica 2011;96:219-20
61. Hutchinson CB, Wang E. Primary mediastinal (thymic) large B-cell lymphoma: a short review with brief discussion of mediastinal gray zone lymphoma. Arch Pathol Lab Med 2011;135:394-8
62. Lau SK, Weiss LM, Chu PG. D2-40 immunohistochemistry in the differential diagnosis of seminoma and embryonal carcinoma: a comparative immunohistochemical study with KIT (CD117) and CD30. Mod Pathol 2007;20:320-5 (Pubitemid 46348336)
63. Haque T, Chaggar T, Schafers J, et al. Soluble CD30: a serum marker for Epstein-Barr virus-associated lymphoproliferative diseases. J Med Virol 2011;83:311-16
64. Purdue MP, Lan Q, Martinez-Maza O, et al. A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma. Blood 2009;114:2730-2
65. Vermeulen R, Saberi HF, Portengen L, et al. Circulating soluble CD30 and future risk of lymphoma; evidence from two prospective studies in the general population. Cancer Epidemiol Biomarkers Prev 2011; [Epub ahead of print]
66. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615-27 (Pubitemid 34177898)
67. Drugs@FDA. Adcetris highlights of prescribing information. Available from: http://www.accessdata.fda.gov